Abstract: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary tumor in the liver, and radical surgical resection is currently the main way to cure ICC. But ICC has an insidious onset, rapid progression, and many have lost the opportunity for radical surgery when clinically found. Chemotherapy regimens such as gemcitabine combined with cisplatin are often used clinically to treat unresectable ICC, but the efficacy is often not satisfactory. The emergence of new therapies such as targeted therapy and immunotherapy has brought a new direction for the treatment of unresectable ICC. Through the study of the mechanism of ICC tumorigenesis, researchers have discovered potential targets for the treatment of ICC, and clinical drug trials for targets such as EGFR, VEGF, FGFR2, HER2, IDH1/2, BRAF, NTRK, MEK1/2 and other targets have made good progress. Trials of immune checkpoint inhibitors have also shown good efficacy in patients with ICC. The combination of the above therapies can also enable some patients to achieve tumor reduction and obtain surgical opportunities. This article reviews the recent research progress of treatment for unresectable ICC, in order to provide new ideas for the treatment of ICC.

Key words: Intrahepatic cholangiocarcinoma, Chemotherapy, Molecularly targeted therapy, Immunotherapy